TY - JOUR
T1 - Nanovaccines in cancer immunotherapy
T2 - Focusing on dendritic cell targeting
AU - Achmad, Harun
AU - Saleh Ibrahim, Yousif
AU - Mohammed Al-Taee, Muataz
AU - Gabr, Gamal A.
AU - Waheed Riaz, Muhammad
AU - Hamoud Alshahrani, Shadia
AU - Alexis Ramírez-Coronel, Andrés
AU - Turki Jalil, Abduladheem
AU - Setia Budi, Hendrik
AU - Sawitri, Windi
AU - Elena Stanislavovna, Malyutina
AU - Gupta, Jitendra
N1 - Publisher Copyright:
© 2022 Elsevier B.V.
PY - 2022/12
Y1 - 2022/12
N2 - Cancer immunotherapy is proposed to eradicate tumors by stimulating host anti-tumor immunity through utilizing various therapeutic approaches. Cancer vaccines have become a promising approach for cancer immunotherapy among the proposed platforms, either alone or in combination with other therapeutic agents. Due to the suboptimal efficacy of cancer vaccines in clinical trials and the advent of nanotechnology in the biomedicine field, scientists developed nanoplatforms, such as various nanoparticles (NPs), cell-derived components, and nanocomplexes, to deliver vaccine components to target cells and tissues, thereby supporting their anti-tumor efficacy and minimizing adverse side effects. To increase the therapeutic effects of nanovaccines in cancer therapy, dendritic cell (DC) targeting through the modulation of the structure of the vaccines, such as using DC-specific ligands, has attracted extensive interest. Here, we reviewed the various forms of nanovaccines in cancer therapy and their therapeutic effects; we highlighted the properties and functions of DCs as the main antigen-presenting cells in immune responses and focused on targeting DCs in developing nanovaccines.
AB - Cancer immunotherapy is proposed to eradicate tumors by stimulating host anti-tumor immunity through utilizing various therapeutic approaches. Cancer vaccines have become a promising approach for cancer immunotherapy among the proposed platforms, either alone or in combination with other therapeutic agents. Due to the suboptimal efficacy of cancer vaccines in clinical trials and the advent of nanotechnology in the biomedicine field, scientists developed nanoplatforms, such as various nanoparticles (NPs), cell-derived components, and nanocomplexes, to deliver vaccine components to target cells and tissues, thereby supporting their anti-tumor efficacy and minimizing adverse side effects. To increase the therapeutic effects of nanovaccines in cancer therapy, dendritic cell (DC) targeting through the modulation of the structure of the vaccines, such as using DC-specific ligands, has attracted extensive interest. Here, we reviewed the various forms of nanovaccines in cancer therapy and their therapeutic effects; we highlighted the properties and functions of DCs as the main antigen-presenting cells in immune responses and focused on targeting DCs in developing nanovaccines.
KW - Cancer immunotherapy
KW - Cancer vaccine
KW - Dendritic cells
KW - Nanoplatforms
KW - Nanovaccines
UR - http://www.scopus.com/inward/record.url?scp=85141942697&partnerID=8YFLogxK
U2 - 10.1016/j.intimp.2022.109434
DO - 10.1016/j.intimp.2022.109434
M3 - Review article
C2 - 36402068
AN - SCOPUS:85141942697
SN - 1567-5769
VL - 113
JO - International Immunopharmacology
JF - International Immunopharmacology
M1 - 109434
ER -